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ABSTRACT:
TP63 is a member of the TP53 gene family that encodes for up to ten different TA 
and ∆N isoforms through alternative promoter usage and alternative splicing. Besides 
being a master regulator of gene expression for squamous epithelial proliferation, 
differentiation and maintenance, P63, through differential expression of its isoforms, 
plays important roles in tumorigenesis. All P63 isoforms share an immunoglobulin-
like folded DNA binding domain responsible for binding to sequence-specific response 
elements (REs), whose overall consensus sequence is similar to that of the canonical 
p53 RE. Using a defined assay in yeast, where P63 isoforms and RE sequences are the 
only variables, and gene expression assays in human cell lines, we demonstrated that 
human TA- and ∆N-P63α proteins exhibited differences in transactivation specificity 
not observed with the corresponding P73 or P53 protein isoforms. These differences 
1) were dependent on specific features of the RE sequence, 2) could be related to 
intrinsic differences in their oligomeric state and cooperative DNA binding, and 3) 
appeared to be conserved in evolution. Since genotoxic stress can change relative 
ratio of TA- and ∆N-P63α protein levels, the different transactivation specificity of 
each P63 isoform could potentially influence cellular responses to specific stresses.
INTRODUCTION
TP63 is a member of the TP53 gene family [1] that 
encodes for up to ten different TA- and ∆N- isoforms 
(α, β, γ, δ, ε) through differential promoter usage and 
alternative splicing [2]. The TA isoforms contain the 
N-terminal transactivation domain (TA1), whereas the 
∆N isoforms are transcribed from an internal promoter 
(P2) and lack the entire TA1 domain. A second C-terminal 
transactivation domain (TA2), present in all P63α and β 
isoforms, has been reported [3]. 
P63 is a master regulator of gene expression for 
squamous epithelial proliferation, differentiation and 
maintenance; in fact, heterozygous germline TP63 
mutations are causative for a subset of human ectodermal 
dysplasia syndromes, confirming the key role of P63 
in epidermis and limb formation during development 
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[4]. The ∆N-P63α isoform is the variant predominantly 
expressed in basal epithelial cells of skin, breast, prostate 
and urinary tract, its inactivation being associated with the 
developmental defects. Conversely, TA-P63 isoforms are 
barely detectable in the same tissues and have instead been 
identified in the female germ line [5-7], where they play a 
role in quality control in response to DNA damage through 
the modulation of apoptosis [8].
Since the ∆N-P63 isoforms lack the N-terminal 
transactivation domain, it was originally proposed that 
these proteins might act primarily as oncogenes through 
dominant-negative mechanisms [1]. Indeed, these isoforms 
can play an important role in the progression of triple 
negative breast cancers where ∆N-P63α promotes tumor 
survival by inhibiting TA-P73 pro-apoptotic activity [9]. 
However, different studies indicate that ∆N-P63 can be 
transcriptionally active [3, 10-13]. For example, ∆N-P63α 
may directly contribute to tumorigenesis by up-regulating 
the expression of the chaperone protein HSP70, which 
displays proliferative and anti-apoptotic functions [14] 
or by repressing pro-apoptotic genes [15]. However, ∆N-
P63 isoforms may have also tumor suppression function; 
in fact ΔN-P63α has been shown to transcriptionally 
activate genes like VDR and ID-3, causing a decrease in 
cell invasion [16, 17].
The TA-P63 isoforms have been described to induce 
cell cycle arrest, senescence and apoptosis [18, 19]. Recent 
evidence suggested that TA-P63 also inhibits metastasis 
either by transcriptionally activating metastasis suppressor 
genes, such as BHLHE41 (Sharp1) and CCNG2 (Cyclin 
G2) [20] or by directly up-regulating miR-130b and the 
microRNA processing enzyme Dicer [21]. 
Regulation of target genes expression by P63 is 
achieved through the binding to sequence-specific REs 
whose consensus sequence is highly similar to that of p53 
REs (RRRCWWGYYY-n-RRRCWWGYYY; R=purine; 
W=A/T; Y=pyrimidine; n=0-13 bp spacer; CWWG 
= CORE) [22]. Structures of P53, P63 and P73 DNA 
binding domains (DBDs) co-crystallized with DNA target 
sequences revealed overall conserved conformation and 
DNA-protein contact sites, even though subtle structural 
differences were observed [23-25]. In vivo DNA binding 
studies have demonstrated specific features in P53, P73 
and P63 target sites’ recognition [26-31], supporting the 
view that promoter selectivity contributes to the functional 
divergence that is apparent by genetic studies in mice or 
by germ line mutations in humans diseases.
In particular, relative to the P53 consensus, the 
P63 consensus RE was enriched in A/G at position 5 and 
C/T at position 16 [27]. Recently, the observation that 
REs containing two half-sites with one overlapping base 
pair were recognized by P63, but not by P53, provided 
additional evidence that specific recognition of cis-
elements contribute to functional divergence among P53 
family proteins [32]. In particular, ChIP-sequencing data 
from different cellular systems indicated a high correlation 
among P63-bound sites, the majority of which are not 
bound by P53 proteins activated by DNA damage response 
[33].
To examine the contribution of RE sequence features 
to P63-dependent transactivation specificity we took 
advantage of a functional assay in yeast where a single 
P63 isoform can be expressed and its capacity to stimulate 
transcription from isogenic promoter-reporter constructs 
measured [28, 34-36]. Being the promoter landscape 
constant except for the RE being tested, we anticipate that 
differences in transactivation potential could be directly 
related to the nature of the interactions of P63 protein 
with DNA target sites. From the results obtained with P63 
proteins on more than 80 different REs, those obtained 
with P73 and P53 proteins for a selected group of REs, and 
also from the correlation between yeast- and mammalian-
transcription assays, we uncovered that ∆N- and TA-
P63α exhibit different transactivation specificities. These 
changes are dependent on specific features of the target 
RE sequences, were not observed with corresponding 
P73 and P53 proteins, and are likely related to intrinsic 
differences in the oligomeric state and in the cooperative 
DNA binding between ∆N- and TA-P63α proteins. 
RESULTS
∆N- and TA-P63α isoforms exhibit different 
transactivation specificities in a genetically 
defined yeast-based assay.
Initially, we compared TA-P63α and ΔN-P63α 
transactivation abilities towards 53 canonical P53 family 
REs using the yeast functional assay (Table S1A). The 
results clearly showed isoform-dependent transactivation 
capacity with the identification of groups of REs 
exhibiting different ∆N-P63α/TA-P63α activity ratios. 
Next to a group of 14 REs towards which TA-P63α was 
at least 1.5 times more active than ∆N-P63α (Figure 1A, 
gray bars; Table S1A, gray highlight), there was a group 
of 10 REs exhibiting quite similar responsiveness to the 
two isoforms (Figure 1A, white bars; Table S1A, white 
cells), followed by another group of 21 REs that was more 
responsive to ∆N-P63α (Figure 1A, blue bars; Table S1A, 
blue highlight). Eight REs were not active (Table S1A, 
green highlight). We then extended the functional analysis 
of P63α isoforms to 34 additional REs (canonical but 
containing a spacer sequence between the two decameric 
half-sites, or non-canonical, comprising three-quarter sites 
and half-sites, multimers or altered-structure REs) (Table 
S1B). The results confirmed the existence of groups of 
REs with different ∆N-P63α/TA-P63α activity ratios. As 
an example, results obtained with three selected REs from 
each of the different groups are presented in Figure 1B. 
The sequence features of the two groups of canonical REs 
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Figure 1: ∆N-P63α and TA-P63α exhibit differences in transactivation capacity and specificity. A) Ratio between ∆N-P63α 
and TA-P63α  transactivation towards 45 canonical REs. The names of the REs are listed on the left, while the sequences and feature 
information can be found in Table S1A. Results are plotted in a logarithmic scale. Grey or blue bars mark REs that were at least 1.5 times 
more responsive to TA-P63a or to ∆N-P63α, respectively (i.e. ∆N-P63α/TA-P63α  ratio being lower than -0.17 or higher than 0.17 in log 
scale). Differences in ratio comprised in that interval were not considered as significant (white bars). The very high ratio for the top three REs 
is caused by extremely weak responsiveness to TA-P63α  (see Table S1A). B) Example of the yeast-based transactivation assay. ∆N-P63α 
or TA-P63α were expressed under the GAL1 inducible promoter (8 hours at 0.128% galactose) in isogenic yeast reporter strains containing 
the indicated P53-family REs. Light Units were normalized to the optical density of the cultures and also to the activity measured in strains 
transformed with an empty expression vector (RLU). Average and standard errors of four biological replicates are plotted. C) Traditional 
Logo view showing sequence features for the group of 21 REs that were more responsive to ∆N-P63α than to TA-P63α (see panel A and 
Table S1A) or for the 14 REs that were more responsive to TA-P63α than to  ∆N-P63α (see panel A and Table S1A). The logo was generated 
with the WebLogo 3 tool (http://weblogo.berkeley.edu/logo.cgi). D) Custom logo summary highlighting dinucleotide motifs at the CWWG 
CORE and the RR or YY DNA contact sites. The height of the color box reflects the percentage of consensus bases at each position. Font 
size of consensus bases or motifs is proportional to their frequency of occurrence. The consensus sequence motif is indicated below the 
figure. E) Comparison of predicted DNA binding affinity for the p53 REs listed in Table S1A and the ratio of relative transactivation 
measured with TA-P63α and  ∆N-P63α.  Each dot represents a different RE sequence and the color matches the groupings based on the 
∆N-P63α/ΤΑ-P63α transactivation ratio reported in panel A and in Table S1A, plotted on a logarithmic scale. F) Relative transactivation 
potential of ∆N-P63α (left panel) and ΤΑ-P63α (right panel) compared to the predicted values of Log Kd for all REs in panel E.
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(without spacer) (Table S1A) showing different ∆N-P63α/
TA-P63α activity ratios were summarized using two 
logo views, the second of which takes into account the 
sequences of dinucleotide motifs flanking the conserved 
C and G bases of the RE consensus (Figures 1C and 
1D). Overall, ∆N-P63α showed higher activity than TA-
P63α towards REs containing a higher frequency of non-
consensus bases and a reduced frequency of the CATG 
sequence at the CWWG core motif. The estimation of 
relative binding affinities (Log Kd) for the canonical REs 
(Table S1A) based on a binding predictor matrix [37], in 
relation to the ΔN-P63α / TA-P63α activity ratio (Figure 
1E) or to the transactivation capacity of each protein 
(Figure 1F), strongly supports the finding that TA-P63α 
exhibited higher transactivation potential but limited to 
higher affinity REs (Figure 1F, right panel). Conversely, 
∆N-P63α exhibited a generally lower transactivation 
potential but towards a wider range of REs, including 
those with predicted lower Kd (Figure 1F, left panel). 
Moreover, the comparison of the relative transactivation 
capabilities of TA-P63α and ∆N-P63α on CON A 
(2xGGGCATGTCC) and CON B (2xGGGCTAGTCC) 
supports the impact of CWWG sequences in determining 
isoform specificity; in fact, the ratio of ∆N-P63α/TA-
P63α responsiveness changed from 0.28 for CON A to 
4.74 for CON B (Table S1A). Interestingly, differences 
in torsional flexibility were described for P53 consensus 
REs containing CATG or CTAG core motifs, and shown 
to impact on P53 binding cooperativity [38].
Regarding P63α isoforms activity on non-canonical 
sites, both ∆N-P63α and TA-P63α were inactive with half-
site REs (Table S1B). Moreover, ∆N-P63α was slightly 
less sensitive than TA-P63α to the negative impact of 
spacers between half-sites and was more active towards 
three-quarter sites. 
Overall, TA-P63α showed a transactivation 
preference towards high affinity REs while ∆N-P63α 
revealed a preference for REs predicted to have lower 
affinity, but high cooperativity [38].
∆N- and TA-P63β and P73 isoforms, as well as P53 
N-ter and C-ter variants do not exhibit different 
transactivation specificities in yeast.
Given the unexpected differences in transactivation 
specificity observed with P63α variants at the N-terminal 
region, we extended the analysis to other P53 family 
proteins. Firstly, we measured TA-P63β and ∆N-P63β 
transactivation specificities using a selected subset of 35 
REs (Table S2). 
TA-P63β was more active than ∆N-P63β, with the 
exception of four REs (PRODH+4.7, PRODH-3.1, C1 SP2 
and PRODH-0.9) (Table S2). TA-P63β also showed higher 
transactivation capacity than TA-P63α and appeared to be 
less sensitive to the deleterious impact of a spacer between 
half-sites, although it remained inactive on half-sites 
(Tables S1 and S2). On the contrary, ∆N-P63β exhibited 
weak activity on all tested REs, generally much lower than 
∆N-P63α (Tables S1 and S2). Hence, there was no clear 
evidence for a change in specificity for TA- and ∆N-P63β 
Figure 2: ∆N- and TA isoforms of P63β as well as P73α or P73β isoforms do not exhibit transactivation specificity in 
yeast. The indicated P63 (A) or P73 (B) proteins were expressed from stable transformants of isogenic yeast reporter strains and relative 
transactivation was measured as described in Figure 1B. Average and standard errors of four biological replicates are plotted. In panel A, 
the light gray bars indicate results obtained with the P63 proteins that were presented in Figure 1 and are included here to facilitate the 
comparison of results obtained with the P63β isoforms. Additional results are presented in Table S2 and S3.
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unlike the case of the corresponding P63α isoforms 
(Figure 2A).
∆N- and TA-P73α isoforms, along with the 
corresponding β isoforms, were also analyzed on a total 
of 14 selected REs (Table S3). As observed for P63 
proteins, TA-P73β had a higher transactivation capacity 
than TA-P73α (Figure 2B). TA-P73α had always a much 
higher transactivation capacity than ∆N-P73α, the latter 
being barely active in yeast. Furthermore, ∆N-P73β was 
completely inactive in our experimental system. 
In order to rule out that the observed heterogeneity 
in transactivation could be due to differences in protein 
steady-state levels, Western blot analysis was performed. 
Similar expression of TA-P63α and ∆N-P63α isoforms 
was observed in yeast (Figure S1), confirming previous 
results [39]. TA-P63β protein levels appeared to be lower 
than those of ∆N-P63β hence the higher activity of the 
TA-P63β is even underestimated. The inactive ∆N-P73β 
was expressed at fairly good levels.
To determine the relative transactivation potential 
of all the three P53 family gene members, the activity of 
P53 was also measured on a subset of 35 REs previously 
tested with P63 isoforms (Table S4). As expected, P53 
was always a more potent transcription factor compared 
to P63 and P73 isoforms (TA, ∆N, α, β), and the only 
protein active with half-site REs in our assay. These 
data are in agreement with previous results and could be 
related, at least in part, to the higher relative expression 
of P53 proteins in yeast [28]. However, a group of five 
canonical REs (without spacer) was identified (P48, PERP, 
COL18A1, H2, miR-198) that exhibited comparable or 
even higher responsiveness to ∆N-P63α or TA-P63β than 
to P53 (Table S5). Considering REs where both ∆N-P63α/
P53 and TA-P63β/P53 ratios were above the 1.5 threshold 
(P48, PERP and mir-198), we noticed an enrichment of 
CAAG sequences at core motif (3/5, 60%). In the case 
of the miR-198 RE, two single nucleotide changes from 
Figure 3: ∆N- and TA-P63α isoforms exhibit some 
differences in transactivation specificity in HCT116 
P53-/- cells. A) Dual luciferase assays from HCT116 P53-/- cells 
transiently cotransfected with the indicated reporter plasmids 
and P63 expression vectors. P53 was included as control. Renilla 
luciferase was measured to normalize transfection efficiencies. 
Data are expressed as fold of induction relative to the results 
obtained with an empty expression vector. Presented are the 
average and standard deviations of at least three biological 
replicates. B) qPCR analysis of the indicated endogenous target 
genes in HCT116 P53-/- cells transfected with the indicated 
expression plasmids. Data are normalized to GAPDH and 
B2M reference genes and are shown relative to the expression 
measured from cells transfected with an empty vector. Plots 
show the average and standard deviations of three technical 
replicates. The experiment was repeated twice. C) Western Blot 
analysis of total soluble proteins extracted from HCT116 P53-
/- cells transfected with the indicated plasmids. Besides P53 
and P63 proteins, the target proteins P21 and MDM2 and the 
reference controls α-actinin and GAPDH are shown.
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CAAG to CATG in both core motifs led to ~30 fold 
increase in responsiveness to P53 but only to a 2.5 fold 
increase to TA-P63β (Tables S2, S4 and S5).
Lastly, we examined the relative transactivation 
specificity of a ∆N-P53 variant i.e. ∆40-P53 (obtained 
from an alternative translation start site) compared to 
full-length P53. A sample of 10 REs, representative of 
different P63α isoforms’ transactivation specificities, and 
two different levels of expression of the GAL1 inducible 
promoter were used (Figures S2A and B). In all cases, 
∆N-P53 exhibited reduced transactivation capacity, with 
no evidence for a change in transactivation specificity; a 
C-terminal deletion construct (∆C-P53), lacking the basic 
domain was also tested, revealing lower transactivation 
potential and no impact on specificity (Figures S2A and 
B). 
Overall, the functional analysis in yeast allowed us 
to establish differences in sequence-specific transactivation 
for P53 family proteins: i) ∆N- and TA-P63α isoforms 
(but not the corresponding ∆N- and TA-P63β, P73 or P53 
isoforms) exhibited an unexpected difference in relative 
transactivation specificity towards REs with distinct 
sequence features; ii) TA-β-isoforms for both P63 and 
P73 were usually more active than the corresponding α 
isoforms; iii) regarding the ∆N-β isoforms, ∆N-P63β 
showed very low levels of activity while ∆N-P73β was 
virtually inactive. 
Ectopic expression of different P63 isoforms in 
HCT116 P53-/- cells partially supports the RE-
dependent changes in transactivation specificity.
We next asked whether the observations in yeast 
could be confirmed in human cells. For these proof-of-
principle experiments, we chose the colon cancer derived 
HCT116 cell clone where TP53 has been knocked out 
and the expression of endogenous P63 or P73 proteins 
is almost undetectable [39, 40]. Ectopic expression of 
P63 ∆N, TA, α, β quartet was achieved upon transient 
transfection. Gene reporter assays, endogenous gene 
expression (qPCR) and Western blots were used as 
endpoints, the latter also to control the relative expression 
of the P63 proteins. 
With the α isoforms, results with the gene reporter 
assays confirmed the higher transactivation capacity of 
Figure 4: ∆N- and TA-P73 isoforms exhibit differences 
in transactivation capacity but not in specificity 
in HCT116 P53-/- cells. A) Dual luciferase assays from 
transiently transfected HCT116 P53-/- cells with the indicated 
reporter plasmids and P73 isoforms. P53 was included as 
control. Experiments were performed and data are plotted 
as described in Figure 3A. B) qPCR analysis of the indicated 
endogenous target genes in HCT116 P53-/- cells transfected with 
the indicated expression plasmids. See Figure 3B. C) Western 
Blot analysis of total soluble proteins extracted from HCT116 
P53-/- cells transfected with the indicated plasmids. Besides P53 
and P73 proteins, the target proteins P21 and MDM2 and the 
reference controls α-actinin and GAPDH are shown.
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TA-P63α with respect to ∆N-P63α on the P21 and MDM2 
promoter sequences and the quite similar transactivation 
on BAX, as highlighted in yeast (Figure 3A). Also the 
observation that ∆N-P63α was more active than TA-P63α 
towards the AIP1 reporter was consistent with the results 
in yeast (Figure 3A). Conversely, P63α isoforms were 
barely active in HCT116 P53-/- cells towards the PG13 
RE cluster, in contrast with what observed in yeast, where 
both isoforms were active
Endogenous genes expression or Western blot 
analyses confirmed a higher activity of TA-P63α compared 
to ∆N-P63α towards P21 and MDM2 (Figure 3B, 3C). 
Moreover, the expression of ∆N-P63α was also associated 
with higher endogenous induction of AIP1 and NOXA, as 
observed in yeast, and the same trend was observed for 
KILLER (Figure 3B). The BAX gene was more responsive 
to TA-P63 than to ∆N-P63α, unlike what obtained in yeast 
and with the gene reporter assay in mammalian cells. 
These discrepancies could be due to the known presence 
of additional REs in the promoter that are not present in 
the reporter constructs.
Lastly, TA-P63β was the most active isoform also 
in the human cell line, considering the relative low levels 
in the transient transfection experiments (Figure 3C). 
Differently from the yeast results, ∆N-P63β was more 
active than ∆N-P63α towards the majority of reporter 
constructs (Figure 3A), although such a difference was not 
always observed when endogenous genes expression was 
measured (Figure 3B).  
The same experiments were conducted after ectopic 
expression of P73 quartets (TA, ∆N, α, β) (Figure 4). 
Results with the α isoforms confirmed those in yeast, 
Figure 5: Relative expression of endogenous P63 isoforms in cells lines treated with DNA damaging or P53 inducing 
agents. Experiments were conducted in the indicated cell lines with known P53 status (wild type, mutant or null, as indicated). Cells were 
treated with Doxorubicin (DXR), 5-FluoroUracil (5FU) or Nutlin-3a (Nutlin) for 16 hours, as described in Materials and Methods. B2M 
and GAPDH served as reference genes. Three biological replicates were performed. Measurements of the endogenous levels of ∆N-P63 or 
TA-P63 mRNAs in P53 wild type A) or mutant/null cells B). For each cell line the graph indicates the relative expression changes and is 
normalized over the most abundant isoform transcript, set to 1 for the DMSO (mock solvent condition, broken line). C) The endogenous 
levels of the P53 target gene P21 were measured as a positive control of the efficacy of the treatments. Values are indicated as fold change 
relative to DMSO treated cells (set to 1 and indicated by broken line). D) ∆N-P63 protein levels were determined by Western blot in 
JHU-029 cells after treatment with DXR, 5FU or Nutlin. GAPDH was used as loading control. Immunoreactive bands specific for the 
∆N-P63α or ∆N-P63β isoforms are indicated with black arrows. E) Western blot experiment demonstrating the over-expression of P53 after 
transfection and its effect on endogenous ∆N-P63α or ∆N-P63β isoforms in JHU-029 cells. GAPDH was used as loading control.
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showing a higher transactivation capacity of TA-P73s 
with respect to ∆N-P73s on P21, MDM2 and BAX 
target sequences. ∆N-P73α was, in fact, inactive towards 
most reporter constructs (Figure 4A) and endogenous 
genes tested (Figure 4B). The AIP1 promoter construct, 
but not the endogenous gene, showed instead higher 
responsiveness to the ΔN-P73s compared to TA-P73s 
(α and β isoforms) (Figures 4 A and 4B). ∆N-P73β that 
was highly expressed (Figure 4C), exhibited a significant 
activity in the reporter assays (in contrast to what 
observed with yeast), but was weakly active towards most 
endogenous genes (Figure 4B), and did not stimulate the 
expression of P21 and MDM2 proteins (Figure 4C). TA-
P73β was in general the most active isoform also in the 
human cell line.
Overall, the ectopic expression of TA-P63α and 
∆N-P63α in HCT116 P53-/- cells partially supports the RE-
dependent changes in transactivation specificity.
Genotoxic stress and/or P53 activating molecules 
influence the expression of ∆N-P63 isoforms in 
human cell lines. 
The relative expression from the P1 and P2 
promoters of the TP63 gene is well-established in the 
context of squamous epithelial differentiation [41]. Given 
the identification of a functional p53 RE in the P2 promoter 
of TP63 [42-44], we examined whether genotoxic stress 
or P53 activating molecules could affect the relative 
expression of P63 promoter variants (TA or ∆N) by qPCR 
(Figures 5A and 5B). Experiments were performed in 
five human cell lines that differ for P53 status: HEK293T 
and HepG2 (wild type), HaCat (mutated), JHU-011 and 
JHU-029 (null). These cells lines were chosen as they 
endogenously expressed P63 proteins [45]. 
In HEK293T and HepG2 cells, ∆N-P63 was 
expressed at lower levels compared to TA-P63 and its 
expression decreased both after genotoxic stress or Nutlin 
treatment, particularly in HEK293T (Figure 5A). TA-
P63 levels did not show significant variations except for 
HEK293T, where a 50% increase and a 25% decrease 
was observed upon 5FU or Nutlin treatment, respectively 
(Figure 5A). 
In cell lines that are mutated or null for P53, ∆N-P63 
was expressed at much higher levels compared to TA-P63 
(Figure 5B). DXR led to a marked decrease of ∆N-P63 
in all cell lines, while 5FU treatment decreased ∆N-P63 
in HaCat and JHU-011 but not in JHU-029; Nutlin did 
not impact on ∆N-P63 levels in these cell lines (Figure 
5B). TA-P63 level was not particularly affected by the 
treatments, also considering the low expression of this P63 
isoform (Figure 5B).
DXR and 5FU led to the induction of the well-
known P53 target P21 in P53 wild type cell lines, while 
Nutlin was effective only in HepG2 cells that do not 
contain the P53-inhibiting SV40 T-large antigen. These 
clear expression changes were not detected in the P53 
mutated or null cells, with the exception of an induction 
of P21 in DXR-treated JHU-011 cells. 
We selected JHU-029 cells for further studies as 
they showed the highest endogenous levels of ∆N-P63 
through the comparison of the Cycle Threshold in qPCR 
assays. Consistent with the qPCR results (Figure 5B), 
also ∆N-P63 protein levels were reduced by genotoxic 
stress, particularly after the treatment with DXR (Figure 
5D). To provide evidence of a direct contribution of P53 
in the regulation of endogenous ∆N-P63, we ectopically 
expressed the wild type protein in JHU-029 cells, which 
resulted in a severe down-regulation of ∆N-P63 proteins 
(Figure 5E). 
Taken collectively, the results indicate that ∆N-P63 
can be negatively regulated at the mRNA and protein 
levels by DNA damage both in a P53-dependent and 
-independent manner. 
DISCUSSION
The P53 family of proteins is a paradigmatic group 
of sequence-specific transcription factors that are master 
regulators of many different biological responses through 
the modulation of a very large number of target genes. 
While genetic approaches indicate a clear separation 
of functions acquired after the gene duplication events 
throughout evolution that led to the three-genes TP53 
family, biochemical and molecular biology approaches, 
including genome level occupancy and transcriptome 
analyses, indicate a high degree of conservation of the 
core function, i.e. the sequence-specific DNA binding 
[10, 27, 46-51]. Another contribution to the complexity 
of this scenario is represented by the modulation of 
these transcription factors in the context of acute stress 
conditions, such as DNA damage, that can impact 
on transactivation selectivity in vivo. These layers of 
regulation have been studied more in-depth for P53, 
for which post-translational modifications affecting 
protein stability, localization and interactions, along 
with the contribution of context dependent trans-factors, 
are recognized elements that modulate transcriptional 
specificity [52-54]. The contribution of cis-factors, 
namely specific features of the target DNA sites, here 
referred as p53 REs, has also been extensively studied 
[52, 53]. Less is known about the regulation of P63 and 
P73, although DNA damage is a recognized activation 
stimulus and specific post-translational modifications have 
been identified [55-57]. Recently, several studies have 
uncovered that cooperative DNA binding coupled to RE 
sequence differences at specific target genes can modulate 
P53 transactivation selectivity [28, 58-60]. For example, 
TP53 mutations or post-translational protein acetylation 
were associated to changes in cooperative DNA binding 
and to a selective modulation of apoptotic target genes 
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[61]. Also, biophysical measurements led to classify p53 
REs in terms of low or high cooperativity; kinetic features, 
especially off-rates, correlate with transactivation potential 
more than DNA binding affinity measured with purified 
P53 DBDs at low protein concentrations [30]. 
To establish the role of RE sequence in 
transactivation specificity of P63 promoter- (∆N and 
TA) and splice-variants (α and β), an experimentally 
defined assay in yeast was used, where the sequence of 
the RE under study and the expression of a chosen P63 
isoform are the only variable and quantitative luciferase 
reporter assays are the functional endpoint. Our results 
revealed that ∆N-P63α and TA-P63α not only differ 
in transactivation potential, but also in transactivation 
specificity (Figure 1A-D; Table S1A, S1B). By using a 
large number of REs, we were able to highlight sequence 
features that correlated with the changes in transactivation 
specificity. In particular, ∆N-P63α-preferred REs were 
associated with CWWG core motifs characterized by 1) 
a lower torsional flexibility, relative to generic B-DNA 
sequences, as determined from cyclization kinetics 
experiments, [30, 38], 2) higher number of mismatches 
(Table S1A), and 3) in some cases, presence of a short 
spacer among decameric half-sites or absence of one 
pentameric quarter site (Table S1B). Hence, ∆N-P63α, 
compared to TA-P63α, exhibited an intrinsic preference 
for lower affinity (Figure 1E and 1F), high cooperativity 
target sequences. A possible explanation for the observed 
differences is that the preferred quaternary structure would 
be different for these two P63 isoforms, with ∆N-P63α, 
but not TA-P63α, being a tetramer. Notably, it was recently 
reported that P63 isoforms in solution can adopt different 
quaternary structures and specifically that TA-P63α, 
unlike ∆N-P63α, would not form tetramers due to an 
intramolecular inhibiting interaction [8, 62]. Interestingly, 
DNA damage-induced post-translational changes can lead 
to TA-P63α tetramer formation [8, 63]. In this regard, 
∆N-P63α could be considered as a constitutively active 
tetramer. Our functional results in yeast are consistent with 
those data, in that a tetrameric conformation is expected 
to retain the capacity to interact with REs that, due to 
mismatches or non-canonical sequence features, would 
not efficiently enable independent binding of two protein 
dimers. The lack of the entire TA1 transactivation domain 
in ∆N-P63α led, however, to a lower extent of reporter 
genes induction, evident for the REs where both ∆N- and 
TA-P63α were active (Table S1). Also consistent with this 
interpretation are our recent results with P63 mutations 
associated to ectodermal dyplasia syndromes that 
exhibited a more severe defect when expressed in yeast as 
TA-P63α compared to ∆N-P63α isoform (Figure S3) [39]. 
Importantly, ectopic expression of ∆N- and TA-P63α 
in an otherwise untreated HCT116 cell clone, that is null 
for P53 and expresses negligible levels of endogenous P63 
or P73 (9,46), confirmed the differences in transactivation 
specificity using gene reporter assays and, in part, also 
following modulation of endogenous genes. Previous data 
in mammalian systems had also observed higher activity 
of ∆N-P63α compared to TA-P63α for selected target 
genes [11, 64]. Hence, the specific responsiveness of the 
REs can, to some extent, impact on the relative expression 
changes even when the RE is embedded in the natural 
promoter context. However, yeast-based assays and also 
results with cloned promoter fragments in mammalian 
cells were not completely predictive of the responsiveness 
of endogenous target genes, in particular when multiple 
REs are present in the regulatory regions, such as in the 
case of BAX.
Our results regarding the ∆N-P63β isoform are 
strikingly inconsistent between yeast and human cells: in 
fact in yeast ∆N-P63β showed much lower transactivation 
capacity than ∆N-P63α (Figure 2A and Table S2) (Figure 
3). The low activity of ∆N-P63β in yeast did not appear 
to be caused by reduced protein expression (Figure S1), 
but we cannot exclude reduced affinity for components 
of the transcription machinery, or lack of necessary 
cofactors, or even a defect in nuclear import. Conversely, 
in HCT116 P53-/- cells, ∆N-P63β was much more active 
than ∆N-P63α and in some cases equal to TA-P63β, but 
without a clear evidence for changes in transactivation 
specificity (Figure 3). The results with P63β isoforms in 
HCT116 and with TA-P63β in yeast are also consistent 
with the reported tetrameric nature of P63β variants in 
solution [8, 65]. Furthermore, the comparison between 
TA-P63α and TA-P63β in yeast and in mammalian cells 
evidenced the higher transactivation potential of the β 
splice variant lacking the SAM domain and the carboxy-
terminal inhibitory domain as well as the capacity of TA-
P63β to retain activity towards REs containing spacers 
or non-canonical three-quarter site REs. This feature was 
particularly evident in HCT116 cells with the PG13 RE, 
consisting of a tandem repeat of 13 copies of a low affinity 
RE of 19 nucleotides.
We also studied TA- and ∆N-, α and β variants 
of P73. In the yeast system ∆N-P73α was an extremely 
weak transcription factor and ∆N-P73β was inactive 
(Figure 2B and Table S3). In HCT116 P53-/-, although 
results might be biased by the higher protein expression, 
∆N-P73β exhibited activity with all reporters tested and 
was even more active than TA-P73β with the AIP1 and 
BAX promoter constructs (Figure 4). However, ectopic 
expression of both ∆N-P73α and ∆N-P73β did not lead 
to the induction of most of the endogenous target genes 
tested. Further studies are needed to examine more 
precisely the possibility that promoter and/or splice 
variants of P73 would exhibit differences in transactivation 
specificity and to elucidate the potential for ∆N-P73s to 
modulate gene expression in a physiological setting. TA-
P73α has been reported to be tetrameric by size exclusion 
chromatography, suggesting a closer similarity with 
P53 than with TA-P63α in stress-induced regulation of 
transcriptional activity [65]. 
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All P63 and P73 isoforms tested in yeast were 
inactive on half-site REs (Tables S2, S3 and S4). When 
expressed at high levels both in yeast and in human cells, 
P53 was instead shown to be capable of modulating 
transcription from half-site REs as well as to bind to half-
site REs by ChIP and ChIP-sequencing experiments [66, 
67]. However, the oligomeric state of P53 protein bound 
to half-sites remains to be established. 
Several P53 isoforms have also been identified, 
resulting from alternative splicing of intron 2 or alternative 
translation initiation (∆N-P53, ∆C-P53), an internal 
promoter (P53-∆133), or alternative splicing at the 
carboxy terminus (P53β, P53γ) [68]. Of these isoforms, 
only ∆N-P53 retains the entire DBD and oligomerization 
domains [47]. Very recently, a mouse model with 
homozygous deletion of the basic domain in the P53 C-ter 
was reported to have severe phenotypes, very reminiscent 
of Dyskeratosis congenita [69]. In derived MEFs (mouse 
embryonic fibroblasts), constitutive nuclear levels of 
this C-ter deleted-P53 were slightly higher compared to 
wild type controls, but the possibility of changes also 
at the level of relative transactivation specificity was 
not conclusively investigated. An independent mouse 
model of the same P53 C-ter deletion construct reported 
tissue-specific differences on the transactivation of target 
genes [70]. Those findings along with data obtained with 
P63α isoforms and on the oligomeric state of P53 family 
proteins [65], stimulated us to examine P53 N-ter (∆N-
P53) and C-ter deletion (∆C-P53) constructs using the 
yeast assay in order to investigate possible changes in 
transactivation specificity. The results obtained with ten 
selected REs showed that both P53 deletion constructs 
retained some level of transactivation potential but they 
were less active than wild type P53 and did not exhibit 
differences in specificity (Figure S2). However, the 
possibility of RE-driven allosteric changes that are not 
impacting on transactivation in yeast due to missing 
cofactors cannot be entirely excluded. 
To explore the potential for evolutionary 
conservation of transactivation capacity and specificity 
of P63 proteins, ∆N-P63 from zebrafish (Danio rerio, 
Dr), an organism where the P2 promoter could be 
predominantly or exclusively active [71] was cloned and 
tested in yeast. Moreover, phylogenetic studies have not 
conclusively demonstrated which TP63 promoter is more 
ancient between P1 (TA) and P2 (∆N) [71, 72]. We were 
able to clone a single ∆N-P63 isoform, corresponding 
to ∆N-P63β, and considered the main or the exclusive 
isoform expressed in zebrafish [71]. Nevertheless, the 
protein was an active transcription factor in yeast. A 
comparison of Dr-∆N-P63 with human TA-P63α indicated 
an overall conservation of relative transactivation 
specificity as seen for human ∆N-P63α in the comparison 
with TA-P63α (Figure S4 and Table S1).This observation 
may suggest that Dr ∆N-P63, like human ∆N-P63, 
constitutively adopts a tetrameric conformation.
Alternative TP63 promoter usage in mammals has 
been clearly established as part of differentiation programs, 
notably in the context of squamous cell epithelia, where 
basal layer cells express predominantly ∆N-P63, while 
TA-P63 expression is prevalent in the differentiated cells 
above [41]. We were interested in exploring whether 
changes in relative promoter activity could also occur 
in the context of DNA damage, also in the light of the 
established presence of a p53 RE in the TP63 promoter 
P2 [42-44]. Interestingly, P53 has also been reported to 
modulate the activity of the TP73 P2 promoter [73] [42]. 
Experiments in five cell lines expressing endogenously 
TA- or ∆N-P63 and differing for P53 status indicated that 
genotoxic stress, or P53 activation with Nutlin in P53 wild 
type cells, or P53 ectopic expression in a P53 null cell line, 
can lead to a decrease in ∆N-P63 protein levels, thereby 
changing the ratio between TA and ∆N isoforms (Figure 
5). Given the different transactivation specificities and 
biological functions of ∆N- and TA-P63 these changes in 
relative expression might influence the cellular response 
by modulation of expression of target genes.
Our results indicate that the regulation of 
P63 promoters’ usage could affect P63-dependent 
transactivation specificity, exploiting the differences in 
oligomeric state between ∆N- and TA-P63α [65] and 
not simply tune the levels of target gene expression.
This regulatory mechanism would however require a 
co-evolution of promoter RE features among different 
functional groups of P63 target genes to be able to impact 
on biological outcomes. The apparent enrichment for low 
affinity/high cooperativity REs among established P53 
family target genes involved in apoptosis [30, 58, 59, 61] 
could reflect this coevolution and be interpreted in the 
light of the results establishing the ancestral function of 
P63-like proteins as the quality control of the germline via 
induction of apoptosis. 
MATERIALS AND METHODS
Yeast strains, vectors and functional assay.
For analysis of the transactivation ability of P53 
family members (P53, ∆N- and TA-, -α and -β variants 
of P63 and P73) we used 87 haploid S. cerevisiae yeast 
strains (yLM-REs) [28, 34-36, 45, 74]. All strains are 
isogenic except for the different RE located upstream 
of the luciferase reporter gene [29, 36, 66, 75]; new 
yLFM-RE strains were constructed, taking advantage 
of the Delitto perfetto approach [76, 77]. The panel of 
REs includes 53 canonical REs (20 bp) without spacer 
(Table S1A), 15 canonical REs with a spacer and 19 non-
canonical REs comprising three-quarter sites, half-sites, 
multimers and altered-structure REs (Table S1B). 
Yeast manipulations were performed as previously 
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described [28, 34, 39]. Inducible expression of P53 family 
members was achieved under a GAL1-10 promoter using 
a pTSG-based (TRP1) vector. Vectors expressing human 
∆N-P63α, TA-P63α and P53 were already available [29, 
31, 39]. New pTSG-based vectors expressing human ∆40-
P53, ∆C-P53 (∆369-393), ∆N-P63β, TA-P63β, ∆N-P73α, 
TA-P73α, ∆N-P73β and TA-P73β were constructed as 
previously described [39]. ∆N-P63β and TA-P63β cDNAs 
were provided by Prof. Roberto Ravazzolo and Dr. Renata 
Bocciardi (IRCCS G. Gaslini, Genoa, Italy). pTSG-based 
vectors expressing TP63 mutants as ∆N-P63α isoform 
were already available, while the same mutants as TA-
P63α variants were constructed as previously described for 
the pTSG-TA-P63α vector (43). A pTSG vector harboring 
the ∆N-P63β isoform expressed in zebrafish (Danio rerio) 
was also constructed. Plasmid pRS314 (TRP1) was used 
as empty vector. Primer sequences are available upon 
request. 
The transactivation ability of the different P53 
family variants was analyzed by transforming yLFM-
REs strains with the different expression vectors using 
the Lithium acetate method, as previously described [34]. 
The luciferase assay was conducted according to the 
miniaturized protocol we recently developed [34]. Yeast 
transformants were grown (8 or 16 hours as indicated) in 
media containing raffinose (2%) without or with different 
concentrations of galactose as inducer. The transactivation 
ability of P53 family members was measured using the 
Bright Glo Luciferase assay kit (Promega, Milan, Italy) 
and expressed as relative light unit (RLU) normalized to 
optical density (600 nm), subtracting the luminescence 
obtained by the cells transformed with the empty vector 
in each reporter strain. 
Mammalian cell lines and vectors.
Human colon cancer HCT116 P53-/- cell line was 
a gift of Prof. B. Vogelstein (John Hopkins University, 
Baltimore, MD, USA) and was used for transfecting 
constructs expressing P53 family members, followed 
by gene reporter assays, quantitative PCR and Western 
blotting experiments. HepG2 (derived from a human 
hepatocellular carcinoma and wild-type at the TP53 
locus) and HEK293T (derived from human embryonic 
kidney and wild-type at the TP53 locus, but expressing 
the P53-inhibiting SV40 T-large antigen) were obtained 
from Dr. Alessandro Provenzani (CIBIO, University of 
Trento, Italy) and Prof. Juergen Borlak (Hannover Medical 
School, Germany), respectively. HaCat cells (human 
immortalized keratinocytes harboring the compound 
heterozygous TP53 mutations H179Y and R282W) as 
well as the P53-null JHU-011 and JHU-029 cells (Head 
and Neck Squamous Cell Carcinoma-derived human 
cell lines) were obtained from Prof. David Sidransky’s 
laboratory at John Hopkins University (Baltimore, MD, 
USA). HepG2, HEK293T, HaCat, JHU-011 and JHU-029 
were used to test the effect of P53 activating molecules 
on P63 isoforms expression levels. Cells were cultured 
in DMEM or RPMI (GIBCO, Invitrogen, Milan, Italy) 
supplemented with 10% fetal bovine serum (FBS), 2mM 
L-Glutamine and antibiotics (100 units/ml penicillin plus 
100 µg/ml streptomycin) and maintained in a humidified 
atmosphere at 37°C with 5% CO2. Cells were routinely 
checked to exclude the presence of mycoplasm.
pCI-neo plasmids for the expression of ∆N-P63α 
and TA-P63α were already available [39]. pCI-neo 
plasmids expressing ∆N-P63β, TA-P63β, ∆N-P73α, TA-
P73α, ∆N-P73β and TA-P73β  were obtained by XhoI/NotI 
double digestion of pTSG-vectors containing the desired 
cDNAs and subsequent ligation of the insert into equally 
digested pCI-neo plasmid. P53 expression was obtained 
using a pCI-neo-derived plasmid similarly generated. The 
empty pCI-neo plasmid was used as control vector.
The pGL3-P21 (2.3 Kb promoter fragment, 
containing both the 5’ and the 3’ p53 REs of the P21 gene), 
pGL3-MDM2 (350 bp region with both p53 REs present in 
intron 1 of the MDM2 gene), PGL3-BAX (400 bp region 
of intron 1 of the BAX gene), PG13 (13 direct repeats of 
the sequence 5’-CCAGGCAAGTCCAGGCAGG-3’) and 
pGL3-AIP1 (containing the p53 RE from yFLM-AIP1 
yeast strain) reporter vectors were used for luciferase 
reporter assay in mammalian cells after transient 
transfection [28]. pRL-SV40 plasmid, harboring the 
luciferase gene from Renilla reniformis under the control 
of a constitutive promoter,  was used to normalize for 
transfection efficiency.
Luciferase assay in the mammalian cell line 
HCT116 P53-/-.
HCT116 P53-/- cells (2x105) were seeded twenty-
four hours prior transfection onto 24-well plates. Cells 
were co-transfected at 50-70% confluence using TransIT-
LT1 (Mirus, Tema Ricerca, Bologna, Italy) with: i) 200 
ng of the expression vectors (for P53 expression, 50 ng 
of vector plus 150 ng of empty vector were used -200 ng 
total DNA amount- in order to avoid excessive toxicity); 
ii) 250 ng of the reporter vector and iii) 50 ng of the 
normalization vector. After additional 24 hours, cells were 
washed with PBS, lysed with Passive Lysis Buffer (PLB) 
1X (Promega). Firefly and Renilla luminescence were 
measured as described previously [78]. 
Transfections and treatments with P53 inducing/
activating compounds.
HCT116 P53-/- and JHU-029 cells were seeded onto 
6 well plates at the concentration of 9x105 cells per well 
and transfected the following day with 2 μg of expression 
vectors for P53 family proteins (in pCI-neo) or pCI-neo 
empty vector, using Fugene HD (Promega). Twenty 
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four hours later, for transfections, or when indicated, for 
treatments, cells were harvested and processed for RNA or 
protein extraction.
P53 wild-type (HEK293T and HepG2) as well as 
P53 mutated (HaCat) or P53 null (JHU-011 and JHU-029) 
cell lines that endogenously express P63 were treated with 
compounds able to stabilize and activate P53. Twenty-four 
hours after seeding, cells were treated with Doxorubicin 
(DXR -1.5μM), 5-FluoroUracil (5FU -375μM) and Nutlin-
3A (Nutlin -10μM) for 16 hours and then processed as 
indicated above. All compounds were purchased from 
Sigma Aldrich (Milan, Italy). DMSO was used as control 
as 5FU and Nutlin were dissolved in such solvent. 
Quantitative PCR analyses. 
To determine optimal transfection efficiency 
pEGFP-N1 vector was used (obtained from Prof. Paolo 
Macchi, CIBIO, University of Trento). Twenty-four 
hours post-transfection cells were harvested and total 
RNA was isolated using the RNeasy mini kit, according 
to the manufacturers’ recommendations (Qiagen, Milan, 
Italy). Two μg of RNA were converted into cDNA using 
the M-MuLV reverse transcriptase (Thermo Scientific, 
Milan, Italy). Quantitative PCR was performed on 25 ng 
of cDNA as previously described [79] using KAPA Sybr 
Green Master mix (Kapa Biosystems, Resnova, Ancona, 
Italy) and specific primers to measure the expression of 
TP63 (ΔN and TA), P21, MDM2, AIP1, BAX, KILLER 
and NOXA genes. B2M (β2-microgobulin) and GAPDH 
(Glyceraldehyde 3-Phosphate DeHydrogenase) were used 
as reference genes. Primer sequences are available upon 
request. Fold changes respect to the empty vector were 
calculated using the ΔΔCT method [80]. 
Antibodies and Western blotting.
Protein extraction from yeast cells.
Yeast transformants were grown for 8 hours 
in selective medium containing 0.128% galactose to 
induce the expression of P63 and P73 specific isoforms. 
An equivalent amount of cells, based on the culture 
absorbance measurement (2.5 OD, OD600nm), was collected 
by centrifugation. Cells were treated with 0.2N NaOH 
at room temperature following the extraction protocol 
described in [81] and 25 μl of extracts were loaded on 
7.5% poly-acrylamide gels. Transfer onto nitrocellulose 
membranes was achieved using the i-Blot semi-dry system 
(InVitrogen, Life Technologies, Milan, Italy). Specific 
antibodies directed against P63 (clone 4A4: sc-8431, Santa 
Cruz Biotechnology, Milan, Italy) or P73 isoforms (clone 
ER-15: OP109, Calbiochem, Millipore, Milan, Italy), 
were diluted in 1% non-fat skim milk dissolved in PBS-T. 
PGK1 (Phospho Glycerate Kinase 1) was used as loading 
control (clone 22C5D8, Life Technologies, Milan, Italy).  
Protein extraction from mammalian cells.
Pellets from transfected or treated cells were washed 
with PBS and used for total protein extraction in RIPA 
lysis buffer supplemented with Protease Inhibitors cocktail 
(Roche, Milan, Italy). Besides the antibodies against P63 
and P73 described above, antibodies against P53 (clone 
DO-1: sc-126), P21 (clone C-19: sc-397), MDM2 (clone 
SMP-14: sc-965), GAPDH (clone 6C5: sc-32233) or 
α-actinin (clone H-2: sc-17829) (all from Santa Cruz 
Biotechnology) were used for immunodetection after 
dilution in 1% non-fat skimmed milk dissolved in PBS-T. 
Immuno-reactive bands from yeast as well as mammalian 
extracts were detected by the ChemiDoc XRS+ System 
(BioRad, Milan, Italy), using the ECL Select detection 
reagent (Amersham, GE Health Care, Milan, Italy). 
ACKNOWLEDGEMENTS
We wish to thank Drs. Umberto Cardellino, 
Raffaella Cinquetti, Silvano Paternoster and Francesca 
Precazzini for excellent technical support. 
Funding
This work was supported by the Italian Association 
for Cancer Research, AIRC (IG grant # 12869 to AI, 
IG#5506 to G.F.) Partially supported by Compagnia S. 
Paolo, Turin, Italy (Project 2012.1590 “Le interazioni 
molecolari della proteina p53 mutata come bersaglio 
di nuove terapie antitumorali personalizzate”). IR is 
supported by a Fellowship from the Pezcoller Foundation, 
Trento, Italy
REFERENCES
1. Yang A, Kaghad M, Wang Y, Gillett E, Fleming MD, 
Dotsch V, Andrews NC, Caput D and McKeon F. p63, a 
p53 homolog at 3q27-29, encodes multiple products with 
transactivating, death-inducing, and dominant-negative 
activities. Mol Cell. 1998; 2(3):305-316.
2. Mangiulli M, Valletti A, Caratozzolo MF, Tullo A, Sbisa 
E, Pesole G and D’Erchia AM. Identification and functional 
characterization of two new transcriptional variants of the 
human p63 gene. Nucleic Acids Res. 2009; 37(18):6092-
6104.
3. Ghioni P, Bolognese F, Duijf PH, Van Bokhoven H, 
Mantovani R and Guerrini L. Complex transcriptional 
effects of p63 isoforms: identification of novel activation 
and repression domains. Mol Cell Biol. 2002; 22(24):8659-
8668.
4. Rinne T, Brunner HG and van Bokhoven H. p63-associated 
disorders. Cell Cycle. 2007; 6(3):262-268.
5. Beyer U, Moll-Rocek J, Moll UM and Dobbelstein 
Oncotarget2128www.impactjournals.com/oncotarget
M. Endogenous retrovirus drives hitherto unknown 
proapoptotic p63 isoforms in the male germ line of 
humans and great apes. Proc Natl Acad Sci U S A. 2011; 
108(9):3624-3629.
6. Candi E, Cipollone R, Rivetti di Val Cervo P, Gonfloni S, 
Melino G and Knight R. p63 in epithelial development. Cell 
Mol Life Sci. 2008; 65(20):3126-3133.
7. Levine AJ, Tomasini R, McKeon FD, Mak TW and Melino 
G. The p53 family: guardians of maternal reproduction. 
Nature reviews Molecular cell biology. 2011; 12(4):259-
265.
8. Deutsch GB, Zielonka EM, Coutandin D, Weber TA, 
Schafer B, Hannewald J, Luh LM, Durst FG, Ibrahim M, 
Hoffmann J, Niesen FH, Senturk A, Kunkel H, Brutschy B, 
Schleiff E, Knapp S, et al. DNA damage in oocytes induces 
a switch of the quality control factor TAp63alpha from 
dimer to tetramer. Cell. 2011; 144(4):566-576.
9. Leong CO, Vidnovic N, DeYoung MP, Sgroi D and Ellisen 
LW. The p63/p73 network mediates chemosensitivity to 
cisplatin in a biologically defined subset of primary breast 
cancers. J Clin Invest. 2007; 117(5):1370-1380.
10. Barton CE, Johnson KN, Mays DM, Boehnke K, Shyr 
Y, Boukamp P and Pietenpol JA. Novel p63 target 
genes involved in paracrine signaling and keratinocyte 
differentiation. Cell death & disease. 2010; 1:e74.
11. Dohn M, Zhang S and Chen X. p63alpha and 
DeltaNp63alpha can induce cell cycle arrest and apoptosis 
and differentially regulate p53 target genes. Oncogene. 
2001; 20(25):3193-3205.
12. Romano RA, Ortt K, Birkaya B, Smalley K and Sinha S. An 
active role of the DeltaN isoform of p63 in regulating basal 
keratin genes K5 and K14 and directing epidermal cell fate. 
PLoS One. 2009; 4(5):e5623.
13. Birkaya B, Ortt K and Sinha S. Novel in vivo targets of 
DeltaNp63 in keratinocytes identified by a modified 
chromatin immunoprecipitation approach. BMC molecular 
biology. 2007; 8:43.
14. Wu G, Osada M, Guo Z, Fomenkov A, Begum S, Zhao M, 
Upadhyay S, Xing M, Wu F, Moon C, Westra WH, Koch 
WM, Mantovani R, Califano JA, Ratovitski E, Sidransky 
D, et al. DeltaNp63alpha up-regulates the Hsp70 gene in 
human cancer. Cancer Res. 2005; 65(3):758-766.
15. Ramsey MR, He L, Forster N, Ory B and Ellisen LW. 
Physical association of HDAC1 and HDAC2 with p63 
mediates transcriptional repression and tumor maintenance 
in squamous cell carcinoma. Cancer Res. 2011; 
71(13):4373-4379.
16. Higashikawa K, Yoneda S, Tobiume K, Saitoh M, 
Taki M, Mitani Y, Shigeishi H, Ono S and Kamata N. 
DeltaNp63alpha-dependent expression of Id-3 distinctively 
suppresses the invasiveness of human squamous cell 
carcinoma. Int J Cancer. 2009; 124(12):2837-2844.
17. Kommagani R, Leonard MK, Lewis S, Romano RA, Sinha 
S and Kadakia MP. Regulation of VDR by deltaNp63alpha 
is associated with inhibition of cell invasion. J Cell Sci. 
2009; 122(Pt 16):2828-2835.
18. Gressner O, Schilling T, Lorenz K, Schulze Schleithoff 
E, Koch A, Schulze-Bergkamen H, Lena AM, Candi E, 
Terrinoni A, Catani MV, Oren M, Melino G, Krammer 
PH, Stremmel W and Muller M. TAp63alpha induces 
apoptosis by activating signaling via death receptors and 
mitochondria. EMBO J. 2005; 24(13):2458-2471.
19. Guo X, Keyes WM, Papazoglu C, Zuber J, Li W, Lowe 
SW, Vogel H and Mills AA. TAp63 induces senescence 
and suppresses tumorigenesis in vivo. Nat Cell Biol. 2009; 
11(12):1451-1457.
20. Adorno M, Cordenonsi M, Montagner M, Dupont S, Wong 
C, Hann B, Solari A, Bobisse S, Rondina MB, Guzzardo V, 
Parenti AR, Rosato A, Bicciato S, Balmain A and Piccolo 
S. A Mutant-p53/Smad complex opposes p63 to empower 
TGFbeta-induced metastasis. Cell. 2009; 137(1):87-98.
21. Su X, Chakravarti D, Cho MS, Liu L, Gi YJ, Lin YL, Leung 
ML, El-Naggar A, Creighton CJ, Suraokar MB, Wistuba 
I and Flores ER. TAp63 suppresses metastasis through 
coordinate regulation of Dicer and miRNAs. Nature. 2010; 
467(7318):986-990.
22. el-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW and 
Vogelstein B. Definition of a consensus binding site for 
p53. Nat Genet. 1992; 1(1):45-49.
23. Chen C, Gorlatova N, Kelman Z and Herzberg O. Structures 
of p63 DNA binding domain in complexes with half-
site and with spacer-containing full response elements. 
Proceedings of the National Academy of Sciences of the 
United States of America. 2011; 108(16):6456-6461.
24. Ethayathulla AS, Nguyen HT and Viadiu H. Crystal 
structures of the DNA-binding domain tetramer of the 
p53 tumor suppressor family member p73 bound to 
different full-site response elements. J Biol Chem. 2013; 
288(7):4744-4754.
25. Ethayathulla AS, Tse PW, Monti P, Nguyen S, Inga A, 
Fronza G and Viadiu H. Structure of p73 DNA-binding 
domain tetramer modulates p73 transactivation. Proceedings 
of the National Academy of Sciences of the United States of 
America. 2012.
26. Osada M, Park HL, Nagakawa Y, Yamashita K, Fomenkov 
A, Kim MS, Wu G, Nomoto S, Trink B and Sidransky D. 
Differential recognition of response elements determines 
target gene specificity for p53 and p63. Mol Cell Biol. 2005; 
25(14):6077-6089.
27. Perez CA, Ott J, Mays DJ and Pietenpol JA. (2007). p63 
consensus DNA-binding site: identification, analysis and 
application into a p63MH algorithm.  Oncogene, pp. 7363-
7370.
28. Ciribilli Y, Monti P, Bisio A, Nguyen HT, Ethayathulla AS, 
Ramos A, Foggetti G, Menichini P, Menendez D, Resnick 
MA, Viadiu H, Fronza G and Inga A. Transactivation 
specificity is conserved among p53 family proteins and 
depends on a response element sequence code. Nucleic 
Oncotarget2129www.impactjournals.com/oncotarget
Acids Res. 2013.
29. Jegga AG, Inga A, Menendez D, Aronow BJ and Resnick 
MA. Functional evolution of the p53 regulatory network 
through its target response elements. Proc Natl Acad Sci U 
S A. 2008; 105(3):944-949.
30. Jordan JJ, Menendez D, Sharav J, Beno I, Rosenthal K, 
Resnick MA and Haran TE. Low-level p53 expression 
changes transactivation rules and reveals superactivating 
sequences. Proc Natl Acad Sci U S A. 2012; 109(36):14387-
14392.
31. Menendez D, Inga A and Resnick MA. Estrogen receptor 
acting in cis enhances WT and mutant p53 transactivation at 
canonical and noncanonical p53 target sequences. Proc Natl 
Acad Sci U S A. 2010; 107(4):1500-1505.
32. Chen C, Gorlatova N and Herzberg O. Pliable DNA 
conformation of response elements bound to transcription 
factor p63. J Biol Chem. 2012; 287(10):7477-7486.
33. McDade SS, Henry AE, Pivato GP, Kozarewa I, 
Mitsopoulos C, Fenwick K, Assiotis I, Hakas J, Zvelebil 
M, Orr N, Lord CJ, Patel D, Ashworth A and McCance 
DJ. Genome-wide analysis of p63 binding sites identifies 
AP-2 factors as co-regulators of epidermal differentiation. 
Nucleic Acids Res. 2012; 40(15):7190-7206.
34. Andreotti V, Ciribilli Y, Monti P, Bisio A, Lion M, Jordan 
J, Fronza G, Menichini P, Resnick MA and Inga A. p53 
transactivation and the impact of mutations, cofactors and 
small molecules using a simplified yeast-based screening 
system. PLoS ONE. 2011; 6(6):e20643.
35. Inga A, Storici F, Darden TA and Resnick MA. Differential 
transactivation by the p53 transcription factor is highly 
dependent on p53 level and promoter target sequence. Mol 
Cell Biol. 2002; 22(24):8612-8625.
36. Resnick MA and Inga A. Functional mutants of the 
sequence-specific transcription factor p53 and implications 
for master genes of diversity. Proc Natl Acad Sci U S A. 
2003; 100(17):9934-9939. Epub 2003 Aug 9938.
37. Veprintsev DB and Fersht AR. (2008). Algorithm for 
prediction of tumour suppressor p53 affinity for binding 
sites in DNA.  Nucleic Acids Res, pp. 1589-1598.
38. Beno I, Rosenthal K, Levitine M, Shaulov L and Haran TE. 
Sequence-dependent cooperative binding of p53 to DNA 
targets and its relationship to the structural properties of the 
DNA targets. Nucleic Acids Res. 2011; 39(5):1919-1932.
39. Monti P, Russo D, Bocciardi R, Foggetti G, Menichini 
P, Divizia MT, Lerone M, Graziano C, Wischmeijer A, 
Viadiu H, Ravazzolo R, Inga A and Fronza G. EEC- and 
ADULT-Associated TP63 Mutations Exhibit Functional 
Heterogeneity Toward P63 Responsive Sequences. Hum 
Mutat. 2013.
40. Vilgelm AE, Washington MK, Wei J, Chen H, Prassolov 
VS and Zaika AI. Interactions of the p53 protein family 
in cellular stress response in gastrointestinal tumors. Mol 
Cancer Ther. 2010; 9(3):693-705.
41. Koster MI, Kim S, Mills AA, DeMayo FJ and Roop DR. 
p63 is the molecular switch for initiation of an epithelial 
stratification program. Genes Dev. 2004; 18(2):126-131.
42. Harmes DC, Bresnick E, Lubin EA, Watson JK, Heim 
KE, Curtin JC, Suskind AM, Lamb J and DiRenzo J. 
Positive and negative regulation of deltaN-p63 promoter 
activity by p53 and deltaN-p63-alpha contributes to 
differential regulation of p53 target genes. Oncogene. 2003; 
22(48):7607-7616.
43. Petitjean A, Cavard C, Shi H, Tribollet V, Hainaut P 
and Caron de Fromentel C. The expression of TA and 
DeltaNp63 are regulated by different mechanisms in liver 
cells. Oncogene. 2005; 24(3):512-519.
44. Waltermann A, Kartasheva NN and Dobbelstein M. 
Differential regulation of p63 and p73 expression. 
Oncogene. 2003; 22(36):5686-5693.
45. Raimondi I, Ciribilli Y, Monti P, Bisio A, Pollegioni 
L, Fronza G, Inga A and Campomenosi P. P53 family 
members modulate the expression of PRODH, but not 
PRODH2, via intronic p53 response elements. PLoS One. 
2013; 8(7):e69152.
46. Levrero M, De Laurenzi V, Costanzo A, Gong J, Wang 
JY and Melino G. The p53/p63/p73 family of transcription 
factors: overlapping and distinct functions. J Cell Sci. 2000; 
113(Pt 10):1661-1670.
47. Murray-Zmijewski F, Lane DP and Bourdon JC. p53/p63/
p73 isoforms: an orchestra of isoforms to harmonise cell 
differentiation and response to stress. Cell Death Differ. 
2006; 13(6):962-972.
48. Collavin L, Lunardi A and Del Sal G. p53-family proteins 
and their regulators: hubs and spokes in tumor suppression. 
Cell death and differentiation. 2010; 17(6):901-911.
49. Flores ER. The roles of p63 in cancer. Cell Cycle. 2007; 
6(3):300-304.
50. Flores ER, Tsai KY, Crowley D, Sengupta S, Yang A, 
McKeon F and Jacks T. p63 and p73 are required for p53-
dependent apoptosis in response to DNA damage. Nature. 
2002; 416(6880):560-564.
51. Brandt T, Petrovich M, Joerger AC and Veprintsev 
DB. Conservation of DNA-binding specificity and 
oligomerisation properties within the p53 family. BMC 
Genomics. 2009; 10(1):628.
52. Espinosa JM. (2008). Mechanisms of regulatory diversity 
within the p53 transcriptional network.  Oncogene, pp. 
4013-4023.
53. Menendez D, Inga A and Resnick MA. The expanding 
universe of p53 targets. Nature Rev Cancer. 2009; 9:724-
737.
54. Sullivan KD, Gallant-Behm CL, Henry RE, Fraikin JL and 
Espinosa JM. The p53 circuit board. Biochim Biophys Acta. 
2012; 1825(2):229-244.
55. Gonfloni S, Di Tella L, Caldarola S, Cannata SM, Klinger 
FG, Di Bartolomeo C, Mattei M, Candi E, De Felici M, 
Melino G and Cesareni G. Inhibition of the c-Abl-TAp63 
pathway protects mouse oocytes from chemotherapy-
Oncotarget2130www.impactjournals.com/oncotarget
induced death. Nat Med. 2009; 15(10):1179-1185.
56. Agami R, Blandino G, Oren M and Shaul Y. Interaction 
of c-Abl and p73alpha and their collaboration to induce 
apoptosis [see comments]. Nature. 1999; 399(6738):809-
813.
57. Chen X, Zheng Y, Zhu J, Jiang J and Wang J. p73 is 
transcriptionally regulated by DNA damage, p53, and p73. 
Oncogene. 2001; 20(6):769-774.
58. Schlereth K, Charles JP, Bretz AC and Stiewe T. Life 
or death: p53-induced apoptosis requires DNA binding 
cooperativity. Cell Cycle. 2010; 9(20):4068-4076.
59. Timofeev O, Schlereth K, Wanzel M, Braun A, Nieswandt 
B, Pagenstecher A, Rosenwald A, Elsasser HP and 
Stiewe T. p53 DNA binding cooperativity is essential for 
apoptosis and tumor suppression in vivo. Cell reports. 2013; 
3(5):1512-1525.
60. Weinberg RL, Veprintsev DB, Bycroft M and Fersht AR. 
Comparative binding of p53 to its promoter and DNA 
recognition elements. J Mol Biol. 2005; 348(3):589-596.
61. Schlereth K, Beinoraviciute-Kellner R, Zeitlinger MK, 
Bretz AC, Sauer M, Charles JP, Vogiatzi F, Leich E, 
Samans B, Eilers M, Kisker C, Rosenwald A and Stiewe T. 
DNA binding cooperativity of p53 modulates the decision 
between cell-cycle arrest and apoptosis. Mol Cell. 2010; 
38(3):356-368.
62. Brandt T, Kaar JL, Fersht AR and Veprintsev DB. Stability 
of p53 homologs. PLoS One. 2012; 7(10):e47889.
63. Suh EK, Yang A, Kettenbach A, Bamberger C, Michaelis 
AH, Zhu Z, Elvin JA, Bronson RT, Crum CP and McKeon 
F. p63 protects the female germ line during meiotic arrest. 
Nature. 2006; 444(7119):624-628.
64. Lin YL, Sengupta S, Gurdziel K, Bell GW, Jacks T 
and Flores ER. p63 and p73 transcriptionally regulate 
genes involved in DNA repair. PLoS Genet. 2009; 
5(10):e1000680.
65. Luh LM, Kehrloesser S, Deutsch GB, Gebel J, Coutandin D, 
Schafer B, Agostini M, Melino G and Dotsch V. Analysis 
of the oligomeric state and transactivation potential of 
TAp73alpha. Cell Death Differ. 2013; 20(8):1008-1016.
66. Jordan JJ, Menendez D, Inga A, Nourredine M, Bell D and 
Resnick MA. Noncanonical DNA motifs as transactivation 
targets by wild type and mutant p53. PLoS Genet. 2008; 
4(6):e1000104.
67. Menendez D, Nguyen TA, Freudenberg JM, Mathew 
VJ, Anderson CW, Jothi R and Resnick MA. Diverse 
stresses dramatically alter genome-wide p53 binding and 
transactivation landscape in human cancer cells. Nucleic 
Acids Res. 2013; 41(15):7286-7301.
68. Khoury MP and Bourdon JC. p53 Isoforms: An Intracellular 
Microprocessor? Genes & cancer. 2011; 2(4):453-465.
69. Simeonova I, Jaber S, Draskovic I, Bardot B, Fang M, 
Bouarich-Bourimi R, Lejour V, Charbonnier L, Soudais 
C, Bourdon JC, Huerre M, Londono-Vallejo A and Toledo 
F. Mutant mice lacking the p53 C-terminal domain model 
telomere syndromes. Cell reports. 2013; 3(6):2046-2058.
70. Hamard PJ, Barthelery N, Hogstad B, Mungamuri SK, 
Tonnessen CA, Carvajal LA, Senturk E, Gillespie V, 
Aaronson SA, Merad M and Manfredi JJ. The C terminus 
of p53 regulates gene expression by multiple mechanisms 
in a target- and tissue-specific manner in vivo. Genes Dev. 
2013; 27(17):1868-1885.
71. Lane DP, Madhumalar A, Lee AP, Tay BH, Verma C, 
Brenner S and Venkatesh B. Conservation of all three p53 
family members and Mdm2 and Mdm4 in the cartilaginous 
fish. Cell Cycle. 2011; 10(24):4272-4279.
72. Rutkowski R, Hofmann K and Gartner A. Phylogeny and 
function of the invertebrate p53 superfamily. Cold Spring 
Harb Perspect Biol. 2010; 2(7):a001131.
73. Vossio S, Palescandolo E, Pediconi N, Moretti F, Balsano 
C, Levrero M and Costanzo A. DN-p73 is activated after 
DNA damage in a p53-dependent manner to regulate p53-
induced cell cycle arrest. Oncogene. 2002; 21(23):3796-
3803.
74. Bisio A, De Sanctis V, Del Vescovo V, Denti MA, Jegga 
AG, Inga A and Ciribilli Y. Identification of new p53 target 
microRNAs by bioinformatics and functional analysis. 
BMC Cancer. 2013; 13(1):552.
75. Resnick MA, Tomso D, Inga A, Menendez D and Bell 
D. Functional diversity in the gene network controlled 
by the master regulator p53 in humans. Cell Cycle. 2005; 
4(8):1026-1029.
76. Storici F, Lewis LK and Resnick MA. In vivo site-directed 
mutagenesis using oligonucleotides. Nat Biotechnol. 2001; 
19(8):773-776.
77. Storici F and Resnick MA. The delitto perfetto approach 
to in vivo site-directed mutagenesis and chromosome 
rearrangements with synthetic oligonucleotides in yeast. 
Methods Enzymol. 2006; 409:329-345.
78. Ciribilli Y, Andreotti V, Menendez D, Langen JS, 
Schoenfelder G, Resnick MA and Inga A. The coordinated 
p53 and estrogen receptor cis-regulation at an FLT1 
promoter SNP is specific to genotoxic stress and estrogenic 
compound. PLoS One. 2010; 5(4):e10236.
79. Lion M, Bisio A, Tebaldi T, De Sanctis V, Menendez D, 
Resnick MA, Ciribilli Y and Inga A. Interaction between 
p53 and estradiol pathways in transcriptional responses to 
chemotherapeutics. Cell Cycle. 2013; 12(8):1211-1224.
80. Pfaffl MW. A new mathematical model for relative 
quantification in real-time RT-PCR. Nucleic Acids Res. 
2001; 29(9):e45.
81. Kushnirov VV. Rapid and reliable protein extraction from 
yeast. Yeast. 2000; 16(9):857-860.
